Barragán-Campos HM, Jiménez-Zarazúa O, Mondragón JD

Language: English
References: 121
Page: 140-157
PDF size: 349.63 Kb.

ABSTRACT

Cancer patients with spinal metastases are a diagnostic and treatment challenge for the clinician. This challenge must be addressed through a multidisciplinary, multimodal, and individualized management. The presence of tumor cells in bone metastases results in homeostatic disruption between bone formation and remodeling. Bone destruction is a late event in the formation of lytic bone metastasis, starting when tumor cells proliferate; this in turn activates osteoclasts, seen as trabecular destruction in imaging studies. There may be excessive bone destruction and increased bone formation, which produce blastic lesions. Bone scintigraphy is currently the most widely used diagnostic method and is considered as the reference test for the diagnosis of spinal bone metastasis. However, we believe that in the near future positron emission tomography associated to computed tomography with ¹⁸F-NaF, or magnetic resonance using diffusion-weighted whole-body imaging with background body signal suppression, will replace bone scintigraphy due to their improved diagnostic accuracy. These new diagnostic tools will help prevent bone metastasis complications such as: intractable pain; spinal cord or cauda equina compression; hypercalcemia; pathological fractures; and spinal instability. With regards to the treatment, it can be uni- or multimodal, depending on the type and number of bone metastases. Among the types of treatment available for bone metastasis are chemotherapy, radiotherapy, and invasive procedures. The prognosis of patient survival depends on the histopathology of the primary tumor, the presence of bone metastasis, and the presence of neurological deficits.

REFERENCES

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127: 2893-917.

2. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24:792-800.

3. Harel R, Angelou L. Spine metastases: current treatments and future directions. Eur J Cancer. 2010;46:2696-707.

4. Pointillar V, Fabre T, Palussière J. [Bone metastases]. Encycl Méd Chyr. 2003;14-798:1-10.

5. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27:165-76.

6. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243-9s.

7. Durand JP, Karoubi P, Anract P, et al. [Bone metastasis: Multidisciplinary management, diagnostic and therapeutic approach]. EMC-Aparato Locomotor. 2013;46:1-16.

8. Kwee TC, Takahara T, Katahira K, et al. Whole-body MRI for detecting bone marrow metastases. PET Clin. 2010;5:297-309.

9. Krishnamurthy GT, Tubis M, Hiss J, et al. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA. 1977;237:2504-6.

10. Georgy BA. Metastatic spinal lesions: State-of-the-art treatment options and further trends. Am J Neuroradiol. 2008;29:1605-11.

11. Scuibba DM, Petteys RJ, Dekutoski MB, et al. Diagnosis and management of metastatic spine disease. A review. J Neurosurg Spine. 2010;13:94-108.

12. Maccauro G, Spinelli MS, Mauro S, et al. Physiopathology of spine metastasis. Int J Surg Oncol. 2011;2011:107969.

13. Oge HK, Aydin S, Cagavi F, et al. Migration of pacemaker lead into the spinal venous plexus: Case report with special reference to Batson´s theory of spinal metastasis. Acta Neurochir (Wien). 2001;143:413-6.

14. Prasad D, Schiff D. Malignant spinal-cord compression. Lancet Oncol. 2005;6:15-24.

15. Barragán-Campos HM, Vallée JN, Lo D, et al. Percutaneous vertebroplasty for spinal metastases: Complications. Radiology. 2006; 238:354-62.

16. Sartor O, Hoskin P, Bruland OS. Targeted radionuclide therapy of skeletal metastases. Cancer Treat Rev. 2013;39:18-26.

17. Collignon J, Gennigens C, Jerusalem G. Assessment of response to therapy for bone metastases: Is it still a challenge in oncology? PET Clin. 2010;5:311-26.

18. Rajarubendra N, Bolton D, Lawrentschuck N. Diagnosis of bone metastases in urological malignancies-- An update. Urology. 2010;76:782-90.

19. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: A review. Crit Rev Oncol Hematol. 2005;56:365-78.

20. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev. 2008;34:92-101.

21. Rosner MH, Dalkin AC. Onco-nephrology: The pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7:1722-9.

22. Sze WM, Shelley MD, Held I, et al. Palliation of metastatic bone pain: Single fraction versus multifraction radiotherapy- A systematic review of randomised trials. Clin Oncol. 2003;15:345-52.

23. Baczyk M. Radioisotope therapy of bone metastases. Nucl Med Rev Cent East Eur. 2011;14:96-104.

24. Saarto T, Janes R, Tenhunen M, et al. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain. 2002;6:323-30.

25. Dunning EC, Butler JS, Morris S. Complications in the management of metastatic spinal disease. World J Orthop. 2012;3:114-21.

26. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin. 2011;61:287-314.

27. Hu MI, Glezerman I, Leboulleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013;105:1417-20.

28. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373-9.

29. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998;77:336-40.

30. Fisher GC, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: An evidencebased approach and expert consensus from the Spine Oncology Study Group. Spine. 2010;35:E1221-9.

31. Molina CA, Gokaslan ZL, Sciubba DM. Diagnosis and management of metastatic cervical spine tumors. Orthop Clin N Am. 2012;43:75-87.

32. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol. 2005;2:504-17.

33. Yang HL, Liu T, Wang XM, et al. Diagnosis of bone metastases: A meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011;21:2604-17.

34. Iagaru A, Mittra E, Dick DW, et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252-9.

35. Huang Q, Ouyang X. Biochemical-markers for the diagnosis of bone metastasis: A clinical review. Cancer Epidemiol. 2012;36:94-8.

36. Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone metastases in breast cancer: Techniques and recommendations for diagnosis. Lancet Oncol. 2009;10:606-14.

37. Roberts CC, Daffner RH, Weissman BN, et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol. 2010;7:400-8.

38. Chua S, Gnanasegaran G, Cook GJ. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): Role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:416-30.

39. Tarnawska-Pier ci ska M, Holody L, Braziewicz J. Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG. Nucl Med Rev Cent East Eur. 2011;14:105-8.

40. Baur-Melnyk A. Malignant versus benign vertebral collapse: Are new imaging techniques useful? Cancer Imaging. 2009;9:S49-51.

41. Love C, Din AS, Tomas MB, et al. Radionuclide bone imaging: An illustrative review. Radiographics. 2003;23:341-58.

42. Abikhzer G, Kennedy J, Israel O. 18F NaF PET/CT and conventional bone scanning in routine clinical practice comparative analysis of tracers, clinical acquisition protocols, and performance indices. PET Clin. 2012;7:315-28.

43. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41-55.

44. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977;35:292-8.

45. Palmedo H, Marx C, Ebert A, et al. Whole-body SPECT/CT for bone scintigraphy: Diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41:59-67.

46. Beheshti M, Langsteger W. 18 FNaF PET/CT in the assessment of metastatic bone disease: Comparison with specific PET tracers. PET Clin. 2012;7:303-14.

47. Shirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin N Am. 2007;45:669-76.

48. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135-42.

49. Ohta M, Tokuda Y, Suzuki Y, et al. Whole-body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun. 2001;22:875-9.

50. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19:1249-54.

51. Gaeta CM, Vercher-Conejero JL, Sher AC, et al. Metastatic breast cancer PET, PET/CT, PET/MRI:FDG and new markers. Q J Nucl Med Mol Imaging. 2013;57:352-66.

52. Fogelman I. Skeletal uptake of disphosphonate: A review. Eur J Nucl Med. 1980;5:473-6.

53. Bartels RH, van der Linden YM, van der Graaf WT. Spinal extradural metastasis: Review of current treatment options. CA Cancer J Clin. 2008;58:245-59.

54. Vanel D, Dromain C, Tardivon A. MRI of bone marrow disorders. Eur Radiol. 2000;10:224-9.

55. Alyas F, Saifuddin A, Connell D. MR imaging evaluation of the bone marrow and marrow infiltrative disorders of the lumbar spine. Magn Reson Imaging Clin N Am. 2007;15:199-219.

56. Schweitzer ME, Levine C, Mitchell DG, et al. Bull’s-eyes and halos: useful MR discriminators of osseous metastases. Radiology. 1993;188:249-52.

57. Jung HS, Jee WH, McCauley TR, et al. Discrimination of metastatic from acute osteoporotic compression spinal fractures with MR Imaging. Radiographics. 2003;23:179-87.

58. Shah LM, Hanrahan CJ. MRI of spinal bone marrow: part I, techniques and normal age-related appearances. AJR Am J Roentgenol. 2011;197:1298-308.

59. Balliu E, Vilanova JC, Peláez I, et al. Diagnostic value of apparent diffusion coefficient to differentiate benign from malignant vertebral bone marrow lesions. Eur J Radiol. 2009;69:560-6.

60. Herneth AM, Guccione S, Bednarski M. Apparent diffusion coefficient: A quantitative parameter for in vivo tumor characterization. Eur J Radiol. 2003;45:208-13.

61. Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR Imaging in cancer: Current status and research directions. Radiology. 2011;261:700-18.

62. Koh DM, Collins D. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007;188:1622-35.

63. Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): Technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004;22:275-82.

64. Nakanishi K, Kobayashi M, Nakaguchi K, et al. Whole-body MRI for detecting metastatic bone tumor: Diagnostic value of diffusion- weighted images. Magn Reson Med Sci. 2007;6:147-55.

65. Kwee TC, Takahara T, Ochiai K, et al. Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol. 2009;70:409-17.

66. Balach T, Stacy GS, Peabody TD. The clinical evaluation of bone tumors. Radiol Clin N Am. 2011;49:1079-93.

67. Huang AJ, Kattapuram SV. Musculoskeletal neoplasms: Biopsy and intervention. Radiol Clin N Am. 2011;49:1287-305.

68. Jelinek JS, Murphey MD, Welker JA, et al. Diagnosis of primary bone tumors with image-guided percutaneous biopsy: Experience with 110 tumors. Radiology. 2002;223:731-7.

69. Coleman RE. Management of bone metastases. Oncologist. 2000;5:463-70.

70. Vassiliou V. Management of metastatic bone disease in the elderly with bisphosphonates and receptor activator of NF-kB ligand inhibitors: Effectiveness and safety. Clin Oncol (R Coll Radiol). 2013;25:290-7.

71. Blum RH, Novetsky D, Shasha D, Fleishman S. The multidisciplinary approach to bone metastases. Oncology. 2003;17:845-67.

72. Fizazi K, Carducci M, Smith M, et al. Denosumab versus Zoledronic acid for treatment of bone metastases in men with castration- resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377:813-22.

73. Kurata T, Nakagawa K. Efficacy and safety of Denosumab for the treatment of bone metastases in patients with advanced cancer. Jpn J Clin Oncol. 2012;42:663-9.

74. Baron R, Ferrari S, Rusell RGG. Review. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone. 2011;48:677-92.

75. Peddi P, Lopez-Olivo MA. Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis. Cancer Treat Rev. 2013;39:97-104.

76. Singh K, Samartzis D, Vaccaro AR, et al. Current concepts in the management of metastatic spinal disease: The role of minimally- invasive approaches. J Bone Joint Surg Br. 2006;88:434-42.

77. Rades D. Dose-fractionation schedules for radiotherapy of bone metastases. Breast Care. 2010;5:339-44.

78. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Nat Cancer Inst. 2005;97:798-804.

79. Bartels RH, van der Linden YM, van der Graaf WT. Spinal extradural metastasis: review of current treatment options. CA Cancer J Clin. 2008;58:245-59.

80. Maisano R, Pergolizzi S, Cascinu S. Novel therapeutic approaches to cancer patients with bone metastases. Crit Rev Oncol Hematol. 2001;40:239-50.

81. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46(Suppl 1):38-47S.

82. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45:1358-65.

83. Peh WC, Munk PL, Rashid F, et al. Percutaneous vertebral augmentation: Vertebroplasty, kyphoplasty and kyphoplasty. Radiol Clin N Am. 2008;46:611-35.

84. Shimony JS, Gilula LA, Zeller AJ, et al. Percutaneous vertebroplasty for malignant compression fractures with epidural involvement. Radiology. 2004;232:846-53.

85. Hurley MC, Kaakaji R, Dabus G, et al. Percutaneous vertebroplasty. Neurosurg Clin N Am. 2009;20:341-59.

86. Shaibani A, Ali S, Bhatt H. Vertebroplasty and kyphoplasty for the palliation of pain. Semin Intervent Radiol. 2007;24:409-18.

87. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg. 2003;98(Suppl 1):21-30.

88. Barragán-Campos HM, Le Faou AL, Rose M, et al. Percutaneous vertebroplasty in vertebral metastases from breast cancer: Interest in terms of pain relief and quality of life. Interv Neuroradiol. 2014;20:591-602.

89. Peh WC, Gilula LA. Percutaneous vertebroplasty: Indications, contraindications, and technique. Brit J Radiol. 2003;76:69-75.

90. Ward E, Munk PL, Rashid F, et al. Musculoskeletal interventional radiology: radiofrequency ablation. Radiol Clin N Am. 2008;46:599-610.

91. Thanos L, Mylona S, Galani P, et al. Radiofrequency ablation of osseous metastases for the palliation of pain. Skeletal Radiol. 2008;37:189-94.

92. Kassamali RH, Ganeshan A, Hoey ET, et al. Pain management in spinal metastases: The role of percutaneous vertebral augmentation. Ann Oncol. 2011;22:782-6.

93. Palussière J, Pellerin-Guignard A, Descat E, et al. Radiofrequency ablation of bone tumours. Diagn Interv Imaging. 2012;93:660-4.

94. Gangi A, Basile A, Buy X, et al. Radiofrequency and laser ablation of spinal lesions. Semin Ultrasound CT MR. 2005;26:89-97.

95. Tokuhashi Y, Matsuzaki H, Oda H, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine. 2005;30:2186-91.

96. Wood S, Brown JE. Skeletal metastasis in renal cell carcinoma: Current and future management options. Cancer Treat Rev. 2011;38:284-91.

97. Imkampe A, Bendall S, Bates T. The significance of the site of recurrence to subsequent breast cancer survival. Eur J Surg Oncol. 2007;33:420-3.

98. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61-6.

99. Shack L, Bryant H, Lockwood G. et al. Conditional relative survival: a different perspective to measuring cancer outcomes. Cancer Epidemiol. 2013;37:446-8.

100. Yong M, Jensen AO, Jacobsen JB, et al. Survival in breast cancer patients with bone metastases and skeletal-related events: A population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011;129:495-503.

101. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784-96.

102. Shen Z, Xie H, Wang C, et al. Clinical features and management of prostate cancer with bone metastases: the first report of our institute. Chin Ger J Clin Oncol. 2008;7:590-2.

103. Nieder C, Haukland E, Pawinski A, et al. Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases. BMC Urol. 2010;10:1-7.

104. Norgaard M, Jensen AO, Jacobsen JB, et al. Skeletal related events, bone metastases and survival of prostate cancer: A population-based cohort study in Denmark (1999 to 2007). J Urol. 2010;184:162-7.

105. Saindane AM. Pitfalls in the staging of cancer of thyroid. Neuroimag Clin N Am. 2013;23:123-45.

106. Voutilainen PE, Multanen M, Haapiainen RK, et al. Anaplastic thyroid carcinoma survival. World J Surg. 1999;23:975-9.

107. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2007. Available at: http://seer.cancer.gov/archive/ csr/1975_2007/.

108. Orita Y, Sugitani I, Matsuura M, et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery. 2010;147:424-31.

109. Kuchuk M, Addison CL, Clemons M, et al. Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol. 2013;2:22-9.

110. Beckett P, Tata LJ, Hubbard RB. Risk factors and survival outcome for non-elective referral in non-small cell lung cancer patients. Analysis based on the National Lung Cancer Audit. Lung Cancer. 2014;83:396-400.

111. Bae HM, Lee SH, Kim TM, et al. Prognostic factors from nonsmall cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer. 2012;77:572-7.

112. Spizzo G, Seeber A, Mitterer M. Routine use of Pamidronate in NSCLC patients with bone metastases: Results from retrospective analysis. Anticancer Res. 2009;29:5245-9.

113. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29-55S.

114. Hubbard MO, Fu P, Margevicius S, et al. Five-year survival does not equal cure in non–small cell lung cancer: A surveillance, epidemiology, and end results–based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg. 2012;143:1307-12.

115. Gloeckler Ries LA, Reichman ME, Lewis DR, et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2003;8:541-52.

116. Woodward E, Jagdev S, McParland L, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2011;48:160-6.

117. Négrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Français d´Immunothérapie. Ann Oncol. 2002;13:1460-8.

118. Toyoda Y, Shinohara N, Harabayashi T, et al. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol. 2007;52:163-9.

119. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-40.

120. Bhagat S, Sharma H, Graham J, et al. Current concepts in the management of renal osseous metastases. Orthopaedics Trauma. 2010;24:363-8.

121. Drucker B. Prognostic factors for biologic therapy in kidney cancer. Curr Urol Rep. 2002;3:31-6.